Shionogi has acquired Tetra Therapeutics, the developer of a treatment candidate known as BPN14770 for fragile…
Vanessa Pataia
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Vanessa Pataia
Treatment with Zygel (ZYN002) may help ease the significant effects fragile X syndrome (FXS) has on children, updated results…